18 June 2025 - Bavarian Nordic announced today that it has entered into an agreement to sell its priority review voucher for a total cash consideration of USD 160 million.

Bavarian Nordic was awarded the priority review voucher in February 2025, following the approval by the US FDA of the chikungunya vaccine, Vimkunya for prevention of disease caused by chikungunya virus in people 12 years of age and older.

Read Bavarian Nordic press release